ストックスクリーナーアプリを入手
4.60
0.65%
-0.03
前日終値:
$4.63
開ける：
$4.59
24時間の取引高:
178.14K
Relative Volume:
0.39
時価総額：
$262.24M
収益：
$7.15M
当期純損益:
$-20.60M
株価収益率:
9.6924
EPS:
0.4746
ネットキャッシュフロー:
$-97.99M
1週間 パフォーマンス:
-0.43%
1か月 パフォーマンス:
+11.11%
6か月 パフォーマンス:
+41.54%
1年 パフォーマンス:
+154.14%
1日の値動き範囲:
$4.53
$4.65
1週間の範囲:
$4.44
$4.81
52週間の値動き範囲:
$1.76
$5.495
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
名前
Whitehawk Therapeutics Inc
セクター
電話
551-321-2234
住所
2 HEADQUARTERS PLAZA, MORRISTOWN
Compare WHWK vs VRTX, REGN, ARGX, MRNA, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
4.60 | 275.35M | 7.15M | -20.60M | -97.99M | 0.4746 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-05 | 開始されました | Oppenheimer | Outperform |
| 2024-08-27 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | ダウングレード | Jefferies | Buy → Hold |
| 2024-08-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2023-12-15 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 開始されました | Jefferies | Buy |
| 2021-10-01 | 開始されました | Cowen | Outperform |
| 2021-09-14 | 開始されました | Ladenburg Thalmann | Buy |
| 2021-09-08 | 開始されました | Piper Sandler | Overweight |
すべてを表示
Whitehawk Therapeutics Inc (WHWK) 最新ニュース
Whitehawk (WHWK) Shares: Finishes 2.31% Up at $4.87 on the Day; Next Test: the $4.63 to $5.11 Range Remains in FocusCall Resistance - vinanet.vn
Whitehawk (WHWK) Watch: Gains 2.94% to Reach $4.90 in the Latest Session; Range Check: $4.66 and $5.15 Define the Nearby Reference Levels at the CloseRetail Driven Moves - Vinanet
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
WHWK Q2 2026 Earnings: Narrower-than-Expected Loss Beats Estimates, Shares Rise 4.04%Net Profit Margin - vinanet.vn
WHWK Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers 33.73% EPS Surprise, Shares Rise 4.04% - vinanet.vn
Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) Stock Price, News & Analysis - Kalkine
Whitehawk Therapeutics (WHWK) Jumps 4.5% to $4.66, Edges Toward Key ResistanceBackspread Trade - vinanet.vn
WHWK Stock Edges Up After Hours: Firm Boosts Pipeline Of Cancer Drugs On The Heels Of Capital Raise - Stocktwits
Whitehawk Therapeutics (WHWK) Drops 4.7% to $4.46, Approaches Key Support at $4.24Diagonal Spread Trade - vinanet.vn
WHWK Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineGeographic Revenue Trends - vinanet.vn
Whitehawk Therapeutics (NASDAQ:WHWK) Rating Increased to Hold at Wall Street Zen - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
JonesTrading Maintains Whitehawk Therapeutics(WHWK.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Announces Quarterly Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Aadi Bioscience Inc (3350.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Form 8K Whitehawk Therapeutics Inc For: 6 August By Investing.com - Investing.com Nigeria
Whitehawk Therapeutics 2Q 2026: Revenue $0 Net loss $16.64M, EPS $(0.20) — 10-Q Summary - tradingview.com
Whitehawk Therapeutics reports Q2 2026 net loss $16.6M; cash $190.0M funds into 2H 2028 - TradingView
Whitehawk Therapeutics reports $16.6 million Q2 loss as trials advance - Quiver Quantitative
Whitehawk Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Whitehawk Therapeutics 2Q Loss/Shr 20c >WHWK - Moomoo
Whitehawk Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights - PR Newswire
Whitehawk Therapeutics (WHWK) Slips 1.7% as Shares Hover Between Support and ResistanceWave Extension - dars.gov.et
Akari Therapeutics Highlights WhiteHawk Collaboration and Dual-Payload ADC Strategy in CEO Corner Segment - Quiver Quantitative
Akari Therapeutics Releases CEO Corner Highlighting Strategic WhiteHawk Collaboration and the Expanding Opportunity for Dual-Payload ADC Innovation - Yahoo Finance
WHWK Q1 2026 Earnings: Narrower-than-Expected Loss Points to Cost DisciplineGuidance Update - vinanet.vn
Stempoint Capital LP Sells 519,438 Shares of Whitehawk Therapeutics, Inc. $WHWK - MarketBeat
WHWK Q1 2026 Earnings: Smaller-than-Expected Loss Beats Estimates Amid Pre-Revenue Status - vinanet.vn
Whitehawk Therapeutics Inc (WHWK) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
WHWK|WHWK|Price:3.940|Chg%:+0.090 - TradingKey
WHWK|WHWK|Price:3.710|Chg%:-0.120 - TradingKey
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
WHWK Q1 2026 Earnings: EPS Beat Narrows Loss, But Stock Slips on Lack of Revenue CatalystEarnings Growth Analysis - vinanet.vn
Akari Therapeutics Collaborates with Whitehawk Therapeutics to Expand ADC Payload Platform Potential - Barchart.com
WHWK|Price:3.710|Chg%:-0.120 - TradingKey
WHWK Q1 2026 Earnings: Narrower-than-expected loss highlights cost disciplineBook Value Growth - vinanet.vn
WHWK Q1 2026 Earnings: EPS Surpasses Estimates on Cost Management and Pipeline ProgressRetail Earnings Report - vinanet.vn
Akari and Whitehawk collaborate on ADC research - BioWorld News
Akari Therapeutics Announces Strategic Preclinical Research Collaboration with Whitehawk Therapeutics on Dual-Payload ADC Development - Quiver Quantitative
Akari and Whitehawk to Test Two ADC Payloads in Preclinical Studies - Stock Titan
Whitehawk Therapeutics(WHWK) Stock Options Chain | Quotes & News - Moomoo
Akari Therapeutics Enters Strategic Research Collaboration with Whitehawk Therapeutics - Yahoo Finance
How Low Will Whitehawk (WHWK) Go After -2.57% Sell-Off? 2026-07-20Sector Leader Stocks - po-news-eg.net
Whitehawk Therapeutics (WHWK) 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA summary - Quartr
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Sees Large Increase in Short Interest - MarketBeat
WHWK Initiated Coverage by Leerink Partners -- Rating Set to Out - GuruFocus
Price to book forward of Whitehawk Therapeutics, Inc. – HAM:3350 - TradingView
Leerink Partners Initiates Whitehawk Therapeutics(WHWK.US) With Buy Rating, Announces Target Price $9 - Moomoo
Whitehawk Therapeutics (NASDAQ:WHWK) Earns Outperform Rating from Analysts at Leerink Partners - MarketBeat
WHWK Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Gain on Cost ControlEarnings Cycle Outlook - dars.gov.et
Biocytogen and Whitehawk partner to develop ADCs - Yahoo Finance
Whitehawk Therapeutics Inc (WHWK) 財務データ
収益
当期純利益
現金流量
EPS
Whitehawk Therapeutics Inc (WHWK) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Apr 15 '26 |
Sale |
3.86 |
77,000 |
297,220 |
436,824 |
0.86%
0.31%
大文字化:
|
ボリューム (24 時間):